CRISPR is like an editor that can rewrite DNA letter by letter or gene by gene, to remove harmful mutations or add protective ...

Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.

Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases. Read why I'm bullish on ALLO ...

Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the ...

YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing therapy for primary hyperoxaluria type 1: Shanghai, China Wednesday, February 26, 2025, 1 ...

Madison's top 10 research grants from the National Institutes of Health, for which Trump announced a big cut, five involve ...

Find out about what's behind the increase of securities class action lawsuits in the biotech industry and how to prevent them ...

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...